Well we know any day now OSA news will pop...
TBI ?....so looking forward to news on this development pathway from IHL
216A has so much potential to mitigate the hallmarks of TBI ....those hallmarks include neural synaptic cell death - neuroinflammation - excitotoxicity (neuro dendrite necrosis) leading to major behavioral deficits for memory and new learning, motor neuron impairment and the incidence of post traumatic convulsions and seizures....
'Mechoulams' work ( the godfather of cannabis research) over the years has demanded clinical development for treatment for this indication and IHL have stepping up to the plate.
10 million TBI related deaths / hospitalisations pa globally would also demand the same imo .....and those are the attributable recorded cases ....suspect that is not representative of the underlying reality of the impact TBI / CTE are responsible for.
Mechoulams' collaborative work in partnership involved the discovery of / and ability of anandamide and 2ag to mitigate the initial hallmarks of TBI as described above.
What are anandamide and 2ag ?
they are 3rd stage endogenous like compounds that are synthesised by the bodies endocannabinoid system ....specifically triggered into production when the brain encounters a primary and / secondary 'insult'.
Mechoulams research specifically evidenced the increased / elevated levels of these 2 synthesised endocannabinoid compounds at the site of the primary neural insult / impact area and noted that they ameliorated the degree of damage and cell death that occurred and specifically as a 'compensatory repair mechanism. '
These 2 compounds are present in cbd ( anandamide and 2 ag comprise 20 fatty acids and 20 amino acids.....they specifically bind to the CB2 receptor and have been evidenced to mitigate cell death and inflammation....now neuroinflammation as well.)
It also was shown to have the same effect across the 'secondary TBI insult cascade ' which is specifically responsible for the major behavioral deficits, also described above.
CBD administered in the immediate period after the primary 'insult' can potentially prevent the development of these debilitating and potentially life threatening developments.
By boosting the endocannabinoid response with increased bioavailability of administered IHL 216A ( synergistic combination of cbd and isoflurane ) immediately following the primary insult it potentially will show that the secondary cascade can be mitigated.
what we know as of march 2021
from Professor O'Brien and the Monash Trauma group
snip courtesy of Small caps
looking forward to knowing a lot more as the news flow increases in the IHL 216A TBI medication story
there is currently no medical treatment for this indication.....standard of care ? - nonexistent
Game changing medication?.....Yep - market opportunity $$$$$$
Exciting times for the company and holders of this innovative Pharmaceutical drug development company.
